Cargando…

Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report

BACKGROUND: Pembrolizumab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1). It is used in the management and treatment of various oncologic conditions. To name a few: refractory and advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fellouah, Massine, Auclair, Marie-Hélène, Fortin, Suzanne, Berdugo, Jérémie, de Guerké, Lara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Survey Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457503/ https://www.ncbi.nlm.nih.gov/pubmed/37636497 http://dx.doi.org/10.1016/j.gore.2023.101235

Ejemplares similares

Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report
por: Heisler, Elise, et al.
Publicado: (2023)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

The Impact of Computed Tomography Measurements of Sarcopenia on Postoperative and Oncologic Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Al Khaldi, Maher, et al.
Publicado: (2022)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma
por: Brind'Amour, Alexandre, et al.
Publicado: (2020)

Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report
por: Lehmann, M., et al.
Publicado: (2023)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Combined use of pembrolizumab and lenvatinib: A review
por: Eisinger, Casey, et al.
Publicado: (2023)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
por: Feng, Mingyang, et al.
Publicado: (2022)

Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer
por: Ing, Brandon I., et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey
por: Parker, Jessica E., et al.
Publicado: (2020)

Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer
por: Matsuura, Yuki, et al.
Publicado: (2023)

A survey on deep multimodal learning for computer vision: advances, trends, applications, and datasets
por: Bayoudh, Khaled, et al.
Publicado: (2021)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

Patient perceptions and understanding of obesity related endometrial cancer
por: Wilkinson, M., et al.
Publicado: (2020)

Patients with endometrial cancer continue to lack understanding of their risks for cancer
por: Sekhon, Subhjit, et al.
Publicado: (2019)

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022)

Locally advanced endometrial cancer with multiple immune-related adverse events coinciding with the complete response to radiotherapy after immune checkpoint inhibitor therapy: A case report
por: Tanaka, Yuji, et al.
Publicado: (2023)

Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature
por: Helbig, M., et al.
Publicado: (2023)

Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
por: Liu, Zhaonan, et al.
Publicado: (2019)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
por: Taylor, Matthew H., et al.
Publicado: (2020)

Combining analytical frameworks to assess livelihood vulnerability to climate change and analyse adaptation options()
por: Reed, M.S., et al.
Publicado: (2013)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk
por: Beavis, Anna L., et al.
Publicado: (2015)

Low grade endometrial stromal sarcoma in pregnancy: A case in support of safe abortion access
por: Furuya, Rachel L., et al.
Publicado: (2023)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
por: Mehta, Naaman, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab a new effective combination of targeted agents
por: Perez-Fidalgo, J.A., et al.
Publicado: (2023)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
por: Shalata, Walid, et al.
Publicado: (2021)

Prevalence of endometrial cancer symptoms among overweight and obese women presenting to a multidisciplinary weight management center
por: Beavis, Anna L., et al.
Publicado: (2020)

Obese endometrial cancer survivors’ perceptions of weight loss strategies and characteristics that may influence participation in behavioral interventions
por: Wilson, Elise M., et al.
Publicado: (2021)

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report
por: Rey-Cárdenas, Macarena, et al.
Publicado: (2023)

Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer
por: Kuroki, Lindsay M., et al.
Publicado: (2015)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0mv28jl0o4b6ncd1vc1948np07